Advertisements



Cancer Genetics receives FDA clearance for Tissue of Origin test

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 16th, 2018

Cancer patients are increasingly being treated based on their inherited genetics — and it’s putting doctors in a difficult position

Hollis Johnson Cancer doctors are increasingly turning to genetics test to help them tr.....»»

Category: topSource: businessinsiderApr 14th, 2018

Angelina Jolie shed light on a rare but potentially misleading mutation that ups your risk of breast cancer — and now 23andMe will test you for it

Lydia Ramsey/Business Insider "Direct to consumer" genetics tests have soared in popularity in recent years as the cost of gene.....»»

Category: topSource: businessinsiderMar 31st, 2018

23andMe’s newest cancer mutation test may be dangerously misleading, according to genetics experts

Lydia Ramsey/Business Insider "Direct-to-consumer" genetics tests have soared in popularity in recent years as the cost of genetics sequenc.....»»

Category: topSource: businessinsiderMar 30th, 2018

Cancer Space Update: New Regulatory Status for 3 Major Drugs

Merck's Keytruda receives approval in Japan for bladder cancer. Seattle Genetics' Adcetris and Novartis' Kisqali get regulatory status .....»»

Category: dealsSource: nytJan 5th, 2018

Roche (RHHBY) Receives FDA Clearance for Ventana MMR Test

Roche's (RHHBY) diagnostic portfolio gets a furth.....»»

Category: dealsSource: nytNov 15th, 2017

Myriad Genetics Boosts myRisk Hereditary Cancer Test Suite

Myriad Genetics (MYGN) introduces riskScore, a breast cancer.....»»

Category: worldSource: nytSep 6th, 2017

Myriad Genetics (MYGN) Grows on Higher Cancer Test Volumes

Myriad Genetics (MYGN) rides high on strength in Molecular Diagnostics with significant contributions from GeneSight. Also, hereditary cancer testing continues to.....»»

Category: topSource: zacksAug 14th, 2017

The FDA Strikes Again at Calithera Biosciences

Calithera Biosciences receives a Fast Track designation for its kidney cancer treatment, sending shares higher......»»

Category: blogSource: 247wallst21 hr. 16 min. ago

Cantel Medical receives FDA 510(k) clearance for ADVANTAGE PLUS Pass-Thru

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 18th, 2018

Science hinted that cancer patients could take less of a $148,000-a-year drug. Its maker tripled its price.

Just as scientific momentum was building to test the effectiveness of lower doses, the new pricing scheme ensured dose reductions wouldn't save patients money or erode companies' revenue......»»

Category: topSource: washpostApr 18th, 2018

Roche receives FDA clearance for cobas CT/NG for use on cobas 6800/8800 systems

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 16th, 2018

I took 23andMe"s test that can now tell whether you may have an increased risk of cancer — here"s what it was like

Hollis JohnsonBack in 2015, I decided to send my spit to 23andMe.....»»

Category: topSource: businessinsiderApr 14th, 2018

Microchip receives U.S. antitrust clearance for Microsemi acquisition

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 13th, 2018

Cantor Fitzgerald Double Downgrades NewLink Genetics After Incyte"s Disappointing Trial

NewLink Genetics Corp (NASDAQ: NLNK), a late-stage biopharmaceutical company that focuses on cancer treatments, said on Friday it will review its clinical program after Merck & Co., Inc. (NYSE: Latest Ratings for .....»»

Category: blogSource: benzingaApr 9th, 2018

Is Exact Sciences Corp. Still a Buy in 2018?

Shareholders in the innovative colon cancer test specialist have enjoyed huge gains over the last few years......»»

Category: topSource: foxnewsApr 8th, 2018

Clovis Oncology ovarian cancer drug receives fast-tracked FDA approval

Clovis Oncology won the fast-tracked verdict it hoped for on Friday when the U.S. Food and Drug Administration approved marketing the company's ovarian cancer drug rucaparib to treat a broader range of patients. The FDA approved the Boulder-based .....»»

Category: topSource: bizjournalsApr 6th, 2018

Myriad Genetics" BRACAnalysis Test Platform Gets PMA in Japan

Myriad Genetics (MYGN) leaves no stone unturned to boost uptake of BRACAnalysis test and strengthen the .....»»

Category: smallbizSource: nytApr 4th, 2018

Cancer Genetics downgraded to Hold from Buy at Maxim

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 3rd, 2018

Cancer Genetics, Inc. 2017 Q4 - Results - Earnings Call Slides

Cancer Genetics, Inc. 2017 Q4 - Results - Earnings Call Slides.....»»

Category: topSource: seekingalphaApr 2nd, 2018

Cancer Genetics" (CGIX) Management on Q4 2017 Results - Earnings Call Transcript

Cancer Genetics" (CGIX) Management on Q4 2017 Results - Earnings Call Transcript.....»»

Category: topSource: seekingalphaApr 2nd, 2018